metastasis
Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications
Premium
The company failed in its first bid for breakthrough device designation but has now split out new specific indications for which it is building more persuasive utility data.
Advanced Gastric Cancer Multiomic Analysis Reveals New Potential Therapeutic Targets
An integrated analysis of peritoneal metastases in advanced gastric cancer patients pointed to new molecular subgroups and treatment targets.
Single Metastatic Cancer Genome Analysis Appears Sufficient to ID Biomarkers, Treatment Options
For many metastatic cancer patients, actionable genomic alterations uncovered in the initial analysis did not change much in later biopsies.
The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.
Biocept Q4 Revenues Spike as COVID-19 Testing Continues to Soar, Core Cancer Tests Lag
The firm's fourth quarter revenues included $18.3 million in commercial test revenue, of which $17.6 million was attributable to COVID-19 tests.